Mode
Text Size
Log in / Sign up

Ferroptosis and the GPX4 axis contribute to inflammation and barrier dysfunction in autoimmune uveitisAir Pollution May Worsen Uveitis Through Cell Death

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that ferroptosis and the GPX4/xCT axis are implicated in retinal inflammation, though direct evidence in human uveitis is limited.

This mini review explores the mechanisms of ferroptosis in the context of autoimmune uveitis. The authors synthesize findings regarding how environmental factors and specific signaling pathways influence retinal inflammation and barrier dysfunction. Specifically, the review notes that PM2.5 exposure in experimental autoimmune uveitis models induces ferroptosis-related changes in CD4+ T cells and enhances T helper 17 pathogenicity. Additionally, the modulation of transforming growth factor-beta receptor 1 (TGFBR1) was shown to alter the glutathione peroxidase 4 (GPX4) and cystine-glutamate antiporter (xCT) axis, impacting lipid peroxidation and inflammatory severity.

The authors acknowledge significant limitations in the current evidence base. They note that direct evidence in autoimmune uveitis is limited and caution that findings from retinal pigment epithelial cells or retinal vascular endothelial cells should not be interpreted as direct proof in human autoimmune uveitis.

Clinical application of ferroptosis inhibitors in autoimmune uveitis is not yet established. The review serves to highlight the underlying molecular pathways of inflammation rather than providing a direct clinical protocol for current practice.

How this fits prior evidence

This review addresses a gap in the understanding of molecular mechanisms in autoimmune uveitis. While previous coverage has focused on the use of corticosteroids for conditions like triple-M syndrome and community-acquired pneumonia, this review explores the underlying role of ferroptosis and the GPX4/xCT axis in retinal inflammation. It does not directly relate to the prior coverage of corticosteroids or surgical interventions for ocular toxoplasmosis.

A new review of studies suggests that air pollution might worsen autoimmune uveitis, an inflammatory eye disease. The research focused on a type of cell death called ferroptosis. In experiments with a mouse model of uveitis, exposure to PM2.5, a common air pollutant, led to ferroptosis-related changes in CD4+ T cells, a type of immune cell. This also made Th17 cells, which promote inflammation, more harmful.

The review also looked at how a protein called TGFBR1 might be involved. Modifying this protein changed the activity of GPX4 and xCT, which are key players in ferroptosis. This affected lipid peroxidation, a process that damages cells, and the severity of inflammation.

It is important to note that this is a mini review, not a new clinical trial. The findings come from laboratory and animal studies, not from people with uveitis. Direct evidence in humans is still limited. The results from other retinal injury models should not be taken as proof that ferroptosis causes autoimmune uveitis in people.

For now, this research is early and does not change current treatment. Corticosteroids remain a standard treatment for uveitis. If you have uveitis and are concerned about air pollution, talk to your doctor. More research is needed before any recommendations can be made.

What this means for you:
Air pollution may worsen uveitis through ferroptosis, but more human research is needed.

Common questions

What is ferroptosis?

Ferroptosis is a type of cell death that involves iron and the buildup of damaged fats in cells. It is different from other forms of cell death. This review looked at whether ferroptosis plays a role in autoimmune uveitis, an inflammatory eye disease.

Does air pollution cause uveitis?

This review does not prove that air pollution causes uveitis. It found that in a mouse model, exposure to PM2.5, a type of air pollution, led to changes in immune cells that might make inflammation worse. More research is needed to know if this happens in people.

Is this study about a new treatment for uveitis?

No. This is a mini review of existing research. It does not test any new treatment. The authors note that direct evidence for ferroptosis in autoimmune uveitis is limited, and clinical use of ferroptosis inhibitors is not yet supported.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Autoimmune uveitis (AU) is a vision-threatening intraocular inflammatory disease characterized by disruption of ocular immune privilege, blood-retinal barrier (BRB) dysfunction, and progressive immune-mediated retinal injury. Although corticosteroids and conventional immunosuppressive therapies remain clinically effective, their long-term use is limited by adverse effects, relapse, and incomplete disease control. Ferroptosis is an iron-dependent form of regulated cell death driven by phospholipid peroxidation. It may provide a mechanistic link between oxidative stress, retinal cell injury, and inflammatory amplification. The retina is potentially susceptible because of its high oxygen demand, redox-active iron, and enrichment in polyunsaturated fatty acids. Direct evidence in AU, however, remains limited. In experimental autoimmune uveitis (EAU), fine particulate matter with an aerodynamic diameter of 2.5 μm or less (PM2.5) induced ferroptosis-related changes in CD4+ T cells and enhanced T helper 17 (Th17) pathogenicity, whereas modulation of transforming growth factor-β receptor 1 (TGFBR1) altered the glutathione peroxidase 4 (GPX4)/cystine–glutamate antiporter (xCT) axis, lipid peroxidation, and inflammatory severity. Studies in retinal pigment epithelial cells, retinal vascular endothelial cells, and other retinal injury models provide supporting evidence but should not be interpreted as direct proof in AU. This Mini Review examines ferroptosis as a potential contributor to BRB dysfunction and retinal inflammation. It separates direct AU/EAU findings from extrapolated evidence and highlights priorities for preclinical validation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.